Christopher Hourigan
Christopher Hourigan is a physician-scientist at the National Heart, Lung, and Blood Institute of the National Institutes of Health in Bethesda, Maryland. He is the Chief of the Laboratory of Myeloid Malignancies". Hourigan has published over 90 scientific papers focusing on measurable residual disease (MRD; previously termed minimal residual disease) and the genomic landscape of acute myeloid leukemia. Education. Hourigan graduated from Oxford University Medical School and received his DPhil for work with Sir John Bell (physician) at the Weatherall Institute of Molecular Medicine at Oxford University. He completed postdoctoral clinical training at Guy's and St  Thomas' Hospital in London, Johns Hopkins Bayview Medical Center, and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore. He is ABIM board certified in Internal Medicine, Hematology, and Medical Oncology. Research. Hourigan is best known for work on Measurable Residual Disease (MRD) and precision medicine in Acute Myeloid Leukemia (AML). This included the demonstration that intervention in patients with AML MRD may improve survival, that low-level TP53 mutations are detectable pre-transplantation in patients with sickle cell disease who develop myeloid malignancy after hematopoietic stem cell transplantation, and that patient-personalized single cell sequencing can  distinguish mutations associated with non-malignant cells rather than residual AML. He holds senior leadership positions in the European Leukemia Network (ELN) guidelines committee for AML MRD, the Foundation for the National Institutes of Health (fNIH) biomarkers consortium for AML MRD, the National Cancer Institute (NCI) MyeloMATCH precision medicine initiative, the Center for International Blood and Marrow Transplant Research (CIBMTR) and on the American Society of Hematology (ASH) guidelines committee for AML in older adults. Honors and awards. In 2019, Hourigan received a Presidential Early Career Award for Scientists and Engineers for his research on Measurable Residual Disease in Acute  Myeloid Leukemia. In 2020, Hourigan was awarded the National Heart, Lung, and Blood Institute Orloff Award and honored for one of the top NIH accomplishments of 2020.